Research progress of soluble guanylate cyclase agonists in atherosclerotic diseases
10.20039/j.cnki.1007-3949.2025.07.012
- VernacularTitle:可溶性鸟苷酸环化酶激动剂在动脉粥样硬化性疾病中的研究进展
- Author:
Qing XIA
1
;
Jun SHEN
1
;
Mengyang CAI
1
;
Yuanying JIANG
1
Author Information
1. 杭州市临平区第一人民医院全科老年医学科,浙江省 杭州市 311100
- Publication Type:Journal Article
- Keywords:
soluble guanylate cyclase;
soluble guanylate cyclase agonists;
atherosclerotic disease
- From:
Chinese Journal of Arteriosclerosis
2025;33(7):638-644
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerosis is a chronic inflammatory disease and the root cause of most cardiovascular diseases.Soluble guanylate cyclase(sGC)agonists play an important role in the regulation of atherosclerotic diseases by nitric oxide(NO)/sGC/cyclic guanosine phosphate(cGMP)signaling pathway.sGC plays an anti-atherosclerotic role in reducing blood lipid levels,improving endothelial dysfunction,reducing inflammatory responses,inhibiting platelet activation,in-hibiting smooth muscle cell proliferation and apoptosis via activating downstream cGMP.This article reviews the effect of sGC agonists on atherosclerosis and its mechanism,in order to provide a theoretical basis for the clinical application of sGC agonists.
